Home High Alpha In Shorting Infinity Pharmaceuticals With Potential Failure Of Upcoming Trials
 

Keywords :   


High Alpha In Shorting Infinity Pharmaceuticals With Potential Failure Of Upcoming Trials

2015-01-10 22:41:32| Biotech - Topix.net

Although Infinity has a collaboration agreement with AbbVie for IPI-145 in blood malignancies, I have doubts about the potential of the selective PI3K inhibitor following the failure in RA. If IPI-145 also fails in blood malignancies then Infinity is effectively worth only the cash on its balance sheet.

Tags: high potential failure alpha

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
18.05Eastern North Pacific Tropical Weather Outlook
18.05Atlantic Tropical Weather Outlook
18.05Producers to be paid grid premiums for AngusLink beef scores
18.05This Week in Agribusiness, May 18, 2024
18.05This Week in Agribusiness, May 18, 2024
18.05Unpaid carers being forced to repay 250m to DWP
18.05Weekly Recap: Hempel, Axalta, KANSAI HELIOS Top This Weeks Stories
18.05Eastern North Pacific Tropical Weather Outlook
More »